Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by ferdie1on Jan 09, 2011 6:50pm
243 Views
Post# 17945988

RE: RE: NI 43-101 on SEDAR as of Jan 7th - MUST RE

RE: RE: NI 43-101 on SEDAR as of Jan 7th - MUST REStanley

you as anyone would know, February completion of surface ramp will probably mean March (1st quarter) time to complete stripping and begin in earnest blasting of next phase of pit means early May, I do not mean to discourage people all I was trying to get across is that The price of shares might drop a bit more into the early spring, I think they have a solid plan going forward, the only thing that worries me about all the Ni 43-101s to date is the backfill (or lack of) of the stopes, these stopes continued production are very dependent upon timely backfilling. I am suprised to see none of the reports mention driving a backfill raise, the earlier one by SRK mentions backhauling, which is not very efficient, storage of backfill is the problem, silo-raise could alleviate this.
 
Having worked there a few times before the carbonate zones (50% of the ore) are very hard to follow, while the flow ore is more continuous, thats why i said it would be tough mining.

Cheers
Ferdie
Bullboard Posts